Sustainability: A Key Differentiator as Biopharma Faces  Momentum Challenges, Global Survey by Cytiva Reports 

• Companies with a proven commitment to sustainability see benefits in revenue, profit,  share price, brand reputation, and talent attraction 
• Collaboration with stakeholders and suppliers identified as key requirement to  accelerating progress  
• Survey respondents acknowledge slow or stalled progress on sustainability initiatives  leads to negative outcomes 

In the Global Biopharma Sustainability Review, more than 800 pharma and biopharma  professionals articulate the benefits of meeting sustainability targets – and the risks of not  clearly measuring progress on those targets. Cytiva, a global life sciences leader, sponsored the  research which includes insights from executives in 18 countries. 

Sustainability is rising to the top of the global agenda as regulations are evolving and investors,  customers, and talent demand more transparency from companies on the topic. 62% of  respondents identify sustainability as their number one priority over the next five years. 

The findings also show that biopharma leaders recognize why they need to decarbonize, and  while progress is good in some areas, companies struggle to make and measure progress. 

SK bioscience, a global manufacturer of vaccines and biotechnology, contributed their  experience in the Sustainability Review. Yeji Park, member of the Environmental, Social and  Governance (ESG) team at SK bioscience, says: “We are pursuing a ‘Double Bottom Line’  management framework…based on the belief that the advancement of socially desirable  products and solutions will ultimately lead to both sustainability and a positive evolution of our  business model.”

Highlights of findings include: 

• 63% of respondents see sustainability as imperative to differentiation and business  growth.  
• Over the past 12 months, more than half of sustainability leaders who participated in  the Review say their companies have experienced increases in revenue (55%), profit  (57%), share price (56%), brand reputation (58%), and their ability to attract talent  (54%). 
• However, more than three-quarters (76%) of companies cannot accurately measure  sustainability return on investment (ROI).

• Almost two-thirds (64%) believe that poor sustainability performance puts their  business at critical risk. 
• Collaboration with stakeholders across the value chain is required to move the needle in  mitigating climate change. 

Emmanuel Abate, President, Genomic Medicine and Head of Sustainability and Corporate  Responsibility at Cytiva, says: “We performed this research for several reasons. One, it is our  responsibility to meet sustainability targets to protect the planet while supporting our  customers as they discover and develop advanced therapies. Two, we want to drive a  conversation around innovation and strategy on sustainability. 

“These findings highlight where we as an industry must collaborate and push for better progress  and prove the benefits of delivering on sustainability targets to employees, customers, and  investors – both current and future.” 

Accurately measuring sustainability progress emerged as a challenge. Technology was  acknowledged as a tool with great potential but must be accompanied by skills and education. 

Sanofi, a global healthcare company with the purpose to chase the miracles of science to  improve people’s lives also contributed to the Review. Aude Arkam, global head of Eco-Design  and Circular Economy at Sanofi, says: “We can use generative AI for life cycle assessments,  decreasing the time it takes to collect data extracts, and to generate reports. Generative AI also  offers the opportunity to learn from the past and ease decision making.”  

The report concludes with three action points for the industry: 

1. Place sustainability at the top of the corporate agenda and communicate this both  internally and externally. 
2. Focus on measuring emissions, moving away from spend-based methods by  investing in technology and encouraging transparency with suppliers. 
3. Collaborate with value chain partners to establish shared sustainability strategies  and achievable goals. 

Read the full Global Biopharma Sustainability Review at: www.cytiva.com/sustainability-review